Antisense Therapeutics has been granted a U.S. patent covering its ATL1102 drug in the treatment of multiple sclerosis.
The patent extends coverage of the ATL1102 compound for the treatment of relapsing-remitting multiple sclerosis patients until 2029 with the potential for up to a five year extension to 2034.
Antisense also has patent applications under examination in Europe, Japan, Canada, and Australia.
Additional patent protection in relation to the antisense technology and manufacturing is also provided internationally for ATL1102 by Antisense's technology partner Isis Pharmaceuticals.
A previous phase two study has confirmed the drug's activity in potently suppressing brain lesions in relapsing-remitting multiple sclerosis patients....... Read More -
http://www.ms-uk.org/index.cfm/ATL1102
U.S. patent granted for ATL1102 for multiple sclerosis
U.S. patent granted for ATL1102 for multiple sclerosis
MS-UK - http://www.ms-uk.org/
-
HarryZ
- Family Elder
- Posts: 2572
- Joined: Tue May 25, 2004 2:00 pm
- Location: London, ON, Canada
- Contact:
Re: U.S. patent granted for ATL1102 for multiple sclerosis
Any time someone makes this kind of statement to describe MS, beware!MS is an auto-immune disease, where the immune system gets confused and instead of attacking an infection or virus it turns on itself and attacks nerve cells.
Harry